460746-48-9

Basic information

• Product Name: 4-[2-(2-HYDROXYETHYL)-1-BENZOFURAN-5-YL]-BENZONITRILE
• Synonyms: 4-[2-(2-HYDROXYETHYL)-1-BENZOFURAN-5-YL]-BENZONITRILE
• CAS NO: 460746-48-9
• Molecular Formula: C₁₇H₁₃NO₂
• Molecular Weight: 263.29062
• Mol File: 460746-48-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 475.6°C at 760 mmHg
• Flash Point: 241.5°C
• Appearance: /
• Density: 1.27g/cm³
• Vapor Pressure: 7.45E-10mmHg at 25°C
• Refractive Index: 1.669
• CAS DataBase Reference: 4-[2-(2-HYDROXYETHYL)-1-BENZOFURAN-5-YL]-BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(2-HYDROXYETHYL)-1-BENZOFURAN-5-YL]-BENZONITRILE(460746-48-9)
• EPA Substance Registry System: 4-[2-(2-HYDROXYETHYL)-1-BENZOFURAN-5-YL]-BENZONITRILE(460746-48-9)

Safety Data

• Hazardous Substances Data: 460746-48-9(Hazardous Substances Data)

Usage

General Description

4-[2-(2-HYDROXYETHYL)-1-BENZOFURAN-5-YL]-BENZONITRILE is a chemical compound that belongs to the benzofuran and benzonitrile families. It is a benzofuran derivative with a benzonitrile group attached to it. The compound contains a hydroxyethyl group, making it a hydroxyethylbenzofuran, which gives it potential pharmaceutical and medicinal properties. It may have applications in the development of drugs for various conditions and diseases, and it is of interest to researchers and pharmaceutical companies for its potential therapeutic effects. Further research is needed to fully understand its properties and potential uses in the field of medicine.

InChI:InChI=1/C17H13NO2/c18-11-12-1-3-13(4-2-12)14-5-6-17-15(9-14)10-16(20-17)7-8-19/h1-6,9-10,19H,7-8H2

Upstream product

• 927-74-2 3-Butyn-1-ol 
• 460746-47-8 4'-hydroxy-3'-iodo[1,1'-biphenyl]-4-carbonitrile 
• 19812-93-2 4-Cyano-4'-hydroxybiphenyl 
• 126747-14-6 4-cyanophenylboronic acid 
• 460748-15-6 2-(5-bromo-1-benzofuran-2-yl)ethanol 

Downstream Products

• 670342-24-2 toluene-4-sulfonic acid 2-[5-(4-cyano-phenyl)benzofuran-2-yl]ethyl ester 
• 460748-71-4 4-{2-[2-((R)-2-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl}benzonitrile L-tartrate 
• 460746-49-0 2-[5-(4-cyanophenyl)-1-benzofuran-2-yl]ethyl methanesulfonate 
• 460746-46-7 4-{2-[2-(2R-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl}benzonitrile 

Relevant articles and documents

4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention

H3 receptor antagonists based on a 2-aminoethylbenzofuran skeleton have been discovered, which are potent in vitro at human and rat H 3 receptors, with Ki values of 0.1-5.8 nM. Analogues were discovered with potent (0.01-1 mg/kg) cognition and attention enhancing properties in animal models. One compound in particular, 4-(2-[2-(2(R)- methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile (ABT-239), combined potent and selective H3 receptor antagonism and excellent pharmacokinetic and metabolic properties across species, with full efficacy in two behavioral models: a five-trial inhibitory avoidance acquisition model in rat pups at 0.1 mg/kg and a social recognition memory model in adult rats at 0.01 mg/kg. Furthermore, this compound did not stimulate locomotor activity and showed high selectivity for the induction of behavioral efficacy versus central nervous system based side effects. The potency and selectivity of this compound and of analogues from this class support the potential of H3 receptor antagonists for the treatment of cognitive dysfunction.

PROCESS FOR PREPARING AMINE-SUBSTITUTED BENZOFURANS

The present invention relates to processes for preparing amine substituted benzofurans, and more particularly 4-(2-{2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl}-1-benzofuran-5-yl)benzonitrile, and salts thereof. Compounds prepared by the processes of the invention have demonstrated activity as histamine-3 receptor ligands.

Histamine-3 receptor ligands for diabetes conditions

The invention relates to a method of treating a diabetic condition by administering a therapeutically effective amount of a histamine-3 receptor antagonist, including benzofuran and benzopyran derivatives of formula (I), aminoalkoxybiphenylcarboxamide compounds of formula (III), and aminoetherbiphenyl compounds of formula (IV) as described herein.